Aldevron, a Danaher company and global leader in the production of DNA, RNA and protein for genomic medicine, and Minaris, a global cell and gene therapy contract development and manufacturing ...
Ottawa, Feb. 19, 2025 (GLOBE NEWSWIRE) -- The global viral vector and plasmid DNA manufacturing market size was valued at USD 7.19 billion in 2024 and is expected to be worth around USD 46.02 billion ...
AAVnerGene Inc. today announced the launch of AAVone®2.1, the next-generation evolution of its proprietary AAVone® ...
ROCKVILLE, Md. May 8, 2026 /PRNewswire=YONHAP/ -- USA -- AAVnerGene Inc. today announced the launch of AAVone®2.1, the ...
Dublin, April 20, 2026 (GLOBE NEWSWIRE)-- The "Viral Vector and Plasmid DNA Manufacturing Market (7th Edition): Industry Trends and Global Forecasts, till 2035" report has been added to ...
The use of performance-enhancing drugs in sports is commonly referred by the term ‘doping’, particularly by those regulatory bodies overseeing sports that have made efforts to fight doping. Through ...
Plasmid DNA lies at the heart of viral and mRNA vector production because it provides the coding sequences for gene-based advanced therapy medicinal products (ATMPs). Its manufacture is therefore ...
WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced the launch of its off-the-shelf pHelper offering, which is designed to secure supply and ...
Gene therapy using transiently expressed non-integrative plasmid vectors is the ideal solution for many public health applications. For example, no current therapy for diabetic foot ulcers directly ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results